Characteristics and outcome of acute myeloid leukemia in patients with a prior history of autoimmune disease

References

• Anderson LA, Pfeiffer RM, Landgren O, et al. Risks of myeloid malignancies in patients with autoimmune conditions. Br J Cancer 2009;100:822–828.
   PubMed Web of Science ®Google Scholar
• Kristinsson SY, Bjorkholm M, Hultcrantz M, et al. Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. J Clin Oncol 2011;29:2897–2903.
   PubMed Web of Science ®Google Scholar
• Peters U, Askling J, Gridley G, et al. Causes of death in patients with celiac disease in a population-based Swedish cohort. Arch Intern Med 2003;163:1566–1572.
   PubMed Web of Science ®Google Scholar
• Gridley G, McLaughlin JK, Ekbom A, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993;85:307–311.
   PubMed Web of Science ®Google Scholar
• Askling J, Fored CM, Baecklund E, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005;64:1414–1420.
   PubMed Web of Science ®Google Scholar
• Isomaki H, Hakulinen T, Joutsenlahti U. Cancer morbidity in rheumatoid patients. Duodecim 1979;95:157.
   PubMedGoogle Scholar
• Hakulinen T, Isomaki H, Knekt P. Rheumatoid arthritis and cancer studies based on linking nationwide registries in Finland. Am J Med 1985;78:29–32.
   PubMed Web of Science ®Google Scholar
• Jacobson DL, Gange SJ, Rose NR, et al. Epidemiology and estimated population burden of selected autoimmune diseases in the united states. Clin Immunol Immunopathol 1997;84:223–243.
   PubMedGoogle Scholar
• Ramadan SM, Fouad TM, Summa V, et al. Acute myeloid leukemia developing in patients with autoimmune diseases. Haematologica 2012;97:805–817.
   PubMed Web of Science ®Google Scholar
• Cibere J, Sibley J, Haga M. Rheumatoid arthritis and the risk of malignancy. Arthritis Rheum 1997;40:1580–1586.
   PubMed Web of Science ®Google Scholar
• Greenstein AJ, Gennuso R, Sachar DB, et al. Extraintestinal cancers in inflammatory bowel disease. Cancer 1985;56:2914–2921.
   PubMed Web of Science ®Google Scholar
• Mir Madjlessi SH, Farmer RG, Weick JK. Inflammatory bowel disease and leukemia. A report of seven cases of leukemia in ulcerative colitis and Crohn's disease and review of the literature. Dig Dis Sci 1986;31:1025–1031.
   PubMed Web of Science ®Google Scholar
• Ellis R, Boggild M. Therapy-related acute leukaemia with mitoxantrone: what is the risk and can we minimise it?Mult Scler 2009;15:505–508.
   PubMed Web of Science ®Google Scholar
• Hattan D, Cerilli GJ. Spontaneous reticulum cell sarcomas developing in C3H-HeJ mice on prolonged immunosuppressive therapy. Transplantation 1971;11:580–581.
   PubMed Web of Science ®Google Scholar
• Nehlsen SL. Immunosuppression, virus and oncogenesis in mice. Transplant Proc 1971;3:811–813.
   PubMed Web of Science ®Google Scholar
• Chalastanis A, Penard-Lacronique V, Svrcek M, et al. Azathioprine-induced carcinogenesis in mice according to Msh2 genotype. J Natl Cancer Inst 2010;102:1731–1740.
   PubMed Web of Science ®Google Scholar
• Hasan SK, Ottone T, Schlenk RF, et al. Analysis of t(15;17) chromosomal breakpoint sequences in therapy-related versus de novo acute promyelocytic leukemia: association of DNA breaks with specific DNA motifs at PML and RARA loci. Genes Chromosomes Cancer 2010;49:726–732.
   PubMed Web of Science ®Google Scholar
• Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762–784.
   PubMed Web of Science ®Google Scholar
• Donahue KE, Gartlehner G, Jonas DE, et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2008;148:124–134.
   PubMed Web of Science ®Google Scholar
• Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010; 116:354–365.
   PubMed Web of Science ®Google Scholar
• Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood 2006;107:3481–3485.
   PubMed Web of Science ®Google Scholar
• Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the united kingdom medical research council AML11 trial. Blood 2001;98:1312–1320.
   PubMed Web of Science ®Google Scholar
• Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology 2007;121:1–14.
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860–867.
   PubMed Web of Science ®Google Scholar
• Soderberg KC, Jonsson F, Winqvist O, et al. Autoimmune diseases, asthma and risk of haematological malignancies: a nationwide case-control study in Sweden. Eur J Cancer 2006;42:3028–3033.
   PubMed Web of Science ®Google Scholar
• Kayser S, Dohner K, Krauter J, et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 2011;117:2137–2145.
   PubMed Web of Science ®Google Scholar
• Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009;361:1249–1259.
   PubMed Web of Science ®Google Scholar
• Fernandez HF, Sun Z, Litzow MR, et al. Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin. Blood 2011;117:5306–5313.
   PubMed Web of Science ®Google Scholar
• Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA 2012;308:898–905.
   PubMed Web of Science ®Google Scholar
• Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. JAMA 2006;295:2275–2285.
   PubMed Web of Science ®Google Scholar
• Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis. Ann Rheum Dis 2009;68:1136–1145.
   PubMed Web of Science ®Google Scholar
• Nannini C, Cantini F, Niccoli L, et al. SIngle-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor a therapy. Arthritis Rheum 2009;61:801–812.
   PubMed Web of Science ®Google Scholar
• Wiens A, Venson R, Correr CJ, et al. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy 2010;30:339–353.
   PubMed Web of Science ®Google Scholar
• Le Blay P, Mouterde G, Barneteche T, et al. Short-term risk of total malignancy and nonmelanoma skin cancers with certolizumab and golimumab in patients with rheumatoid arthritis. J Rheumatol 2012;39:712–715.
   PubMed Web of Science ®Google Scholar